Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro, Srinivas Tantravahi, Jay Yang, Arielle Baim, Sonia Maldonado-Schmidt, Claire Olig, Kathryn Flynn, Yan Gao, Jerald Radich, Ehab Atallah, Jorge Cortes

Blood (2025) 146 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2025-7311

Published: 2025

Journal Articles

XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells

Anthony Pomicter, Kristin Starr, Yurong Ouyang, Josh Monts, James Marvin, Andrea Ellero, Christopher Walker, Srinivas Tantravahi

Blood (2025) 146 (Supplement 1): 7275.

https://doi.org/10.1182/blood-2025-7275

Published: 2025

Journal Articles

Lactate export inhibition reveals a metabolic vulnerability in myelofibrosis

Nathan Krah, Nicole Arellano, William Heaton, Anton Rets, Srinivas Tantravahi, Juliette Pearce, Spencer Gygi, Abigail Runnels, Parker Bowden, Rebekka Schneider, Jared Rutter, Shannon Elf

Blood (2025) 146 (Supplement 1): 357.

https://doi.org/10.1182/blood-2025-357

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Blood (2025) 146 (Supplement 1): 906.

https://doi.org/10.1182/blood-2025-906

Published: 2025

Journal Articles

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Blood (2025) 146 (Supplement 1): 904.

https://doi.org/10.1182/blood-2025-904

Published: 2025

Journal Articles

Real-world outcomes associated with azacitidine and venetoclax in Myelodysplastic Syndromes

Taylor Kujawa, Stacy Prelewicz, Clara Davis, Chia Jie Tan, Madhu Menon, Ramiro Garzon, Afaf Osman, Srinivas Tantravahi, Paul Shami

Blood (2025) 146 (Supplement 1): 8193.

https://doi.org/10.1182/blood-2025-8193

Published: 2025

Journal Articles

Identifying individuals with DDX41 germline predisposition syndrome

Catherine Levy, Jennie Vagher, Anthony Pomicter, Richard King, Peng Li, Kline Dubose, Ira Kraft, Srinivas Tantravahi

Blood (2025) 146 (Supplement 1): 6745.

https://doi.org/10.1182/blood-2025-6745

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Journal Articles

Granulocyte maturation and splicing defects in DDX41-mutated leukemia

Blood (2025) 146 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2025-1439

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Hematological and inflammatory response trajectories in vexas syndrome patients treated with hypomethylating agents

Fieke Hoff, Benjamin Turturice, Ruba Shalhoub, Alice Fike, Kaitlin Quinn, Ivana Darden, Shanni Liu, Boeui Kang, Ashley Degner, Ami Patel, Srinivas Tantravahi, Srinivasa Sanikommu, Colin Wu, Katherine Calvo, Neal Young, Peter Grayson, Emma Groarke, Bhavisha Patel

Blood (2025) 146 (Supplement 1): 1414.

https://doi.org/10.1182/blood-2025-1414

Published: 2025

Journal Articles

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

Michael Mauro, Lisa Rein, Jay Yang, Srinivas Tantravahi, Sonia Maldonado-Schmidt, Claire Olig, Alexander Hinman, Arielle Baim, Jerald Radich, Kathryn Flynn, Ehab Atallah

Blood (2025) 146 (Supplement 1): 7293.

https://doi.org/10.1182/blood-2025-7293

Published: 2025

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells

Lactate export inhibition reveals a metabolic vulnerability in myelofibrosis

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Real-world outcomes associated with azacitidine and venetoclax in Myelodysplastic Syndromes

Identifying individuals with DDX41 germline predisposition syndrome

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Granulocyte maturation and splicing defects in DDX41-mutated leukemia

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Hematological and inflammatory response trajectories in vexas syndrome patients treated with hypomethylating agents

Treatment free remission after asciminib (ABL001) based therapy in chronic Phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-h jean khoury cure CML consortium study HJKC3-0003

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only